Podcasts about emerging treatment options

Personalisierte Behandlungen, genetische Risikofaktoren, geschlechtsspezifische Unterschiede und Vorteile früher, hochwirksamer Therapien. Hier kannst du den kompletten Beitrag nachlesen: https://ms-perspektive.de/ectrims-2024-1 Dieses Jahr kommen auf der ECTRIMS 2024 in Kopenhagen, Dänemark, wieder führende Experten für Multiple Sklerose (MS) aus der ganzen Welt zusammen. Die renommierte Konferenz ist die wichtigste Veranstaltung für Forscher, Ärzte und medizinisches Fachpersonal, die alle auf ein gemeinsames Ziel hinarbeiten: die Verbesserung der Lebensqualität durch bahnbrechende Forschung und Fortschritte bei der Behandlung von MS und verwandten Krankheiten. Die Veranstaltung, zu der rund 9.000 Teilnehmer erwartet werden, verspricht ein reichhaltiges Programm mit inspirierenden Grundsatzreden, spannenden Vorträgen und Posterpräsentationen sowie sorgfältig zusammengestellten wissenschaftlichen und pädagogischen Sitzungen. Darüber hinaus wird es zahlreiche Gelegenheiten zum Networking und zur Kontaktaufnahme mit der internationalen MS-Gemeinschaft geben. Ich habe Dir zu Beginn meiner Berichterstattung über die diesjährige Veranstaltung einige spannende Paper mitgebracht. Von Biomarkern, die bei der Vorhersage des Krankheitsverlaufs helfen, bis hin zu neuen Erkenntnissen über genetische Risikofaktoren und geschlechtsspezifische Unterschiede bei der Behandlung unterstreichen diese Ergebnisse die wachsende Bedeutung einer personalisierten Versorgung bei der Behandlung von MS. Zu den wichtigsten Erkenntnissen gehören die Vorteile frühzeitiger, hochwirksamer Behandlungen für Kinder, mit dem MS-Risiko verbundene, durch die Abstammung bedingte genetische Varianten und die therapeutische Trägheit bei der Behandlung von Frauen mit MS. Diese Studien ebnen den Weg für gezieltere und wirksamere Behandlungsstrategien, die die Ergebnisse für MS-Patienten weltweit verändern könnten. Inhaltsverzeichnis Frühe hochwirksame MS-Behandlung bei Kindern zeigt langfristige Vorteile Neue genetische Entdeckungen ebnen den Weg für personalisierte MS-Behandlungen für verschiedene Bevölkerungsgruppen Bluttests helfen, Fortschreiten von Behinderungen bei MS frühzeitig zu erkennen Ungenutzte Chancen: Warum Frauen mit MS seltener frühzeitig hochwirksame Therapien erhalten Quellen Long-term disability outcomes among children with multiple sclerosis treated with high-efficacy therapy, Sharmin, S. et al. (2024). Presented at ECTRIMS 2024. Mavridi, A., Bompou, M.E., Redmond, A. et al. (2024). Current and Emerging Treatment Options in Pediatric Onset Multiple Sclerosis. Sclerosis; 2(2):88-107. https://doi.org/10.3390/sclerosis2020007 Novel ancestry-specific and putative causal genetic variants for multiple sclerosis identified by an ancestry-informed regression and trans-ethnic fine-mapping analysis, McCauley, J.L., et al. (2024). Presented at ECTRIMS 2024.  Serum neurofilament light chain and glial fibrillary acidic protein levels at disease onset unveil immunologic pathways of disability acquisition in multiple sclerosis, Monreal E., et al. (2024). Presented at ECTRIMS 2024. Meier S., Willemse E.A., Schaedelin S., et al. (2023). Serum Glial Fibrillary Acidic Protein Compared with Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurol., 80(3):287-297. doi:10.1001/jamaneurol.2022.5250 Lublin, F. D., Häring, D. A., Ganjgahi, H., et al. (2022). How patients with multiple sclerosis acquire disability. Brain: A Journal of Neurology, 145(9), 3147-3161. https://doi.org/10.1093/brain/awac016 Is there therapeutic inertia in women with MS? Vukusic, S., et al. (2024). Presented at ECTRIMS 2024.  --- Bis bald und mach das Beste aus Deinem Leben, Nele Mehr Informationen und positive Gedanken erhältst Du in meinem kostenlosen Newsletter. Hier findest Du eine Übersicht zu allen bisherigen Podcastfolgen.

CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/staying-current-what-do-recent-clinical-trial-data-say-about-the-new-and-emerging-treatment-options-for-cias/20298/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.

Anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT) are rare cancers observed predominantly in children and young adults. ALCL accounts for 10–15% of all pediatric non-Hodgkin lymphomas and is commonly diagnosed at an advanced stage of disease. This podcast provides an overview of ALK-positive ALCL and IMT. The authors discuss the current treatment landscape, the role of ALK tyrosine kinase inhibitors, and areas of future research.   This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-024-00275-6. All conflicts of interest can be found online. This podcast is intended for medical professionals.   Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

INTRODUCTIONThis is an accredited continuing education series of two (2) podcasts as downloadable audio files (MP3). Dr. Raj Chovatiya and Dr. David Rosmarin will provide expert interpretation of new data for current and emerging treatment options of vitiligo, along with practical considerations for how new agents can impact patient outcomes. Case presentations will be discussed to help clinicians select the most appropriate treatment as well as address the significant health burdens and complications experienced by many patients during treatment.Launch Date: November 8, 2023Release Date: November 8, 2023Expiration Date: October 31, 2024 FACULTY BIOSDavid Rosmarin, MDChair Department of DermatologyKapens Norrins ScholarIndiana University School of MedicineIndianapolis, Indiana Raj Chovatiya, MD, PhD, MSCI, FAADAssistant Professor of DermatologyNorthwestern University Feinberg School of MedicineChicago, IllinoisThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/expert-insights-on-vitiligo-how-do-emerging-treatment-options-have-the-potential-to-transform-patient-outcomes

INTRODUCTIONThis is an accredited continuing education series of two (2) podcasts as downloadable audio files (MP3). Dr. Raj Chovatiya and Dr. David Rosmarin will provide expert interpretation of new data for current and emerging treatment options of vitiligo, along with practical considerations for how new agents can impact patient outcomes. Case presentations will be discussed to help clinicians select the most appropriate treatment as well as address the significant health burdens and complications experienced by many patients during treatment.Launch Date: November 8, 2023Release Date: November 8, 2023Expiration Date: October 31, 2024 FACULTY BIOSDavid Rosmarin, MDChair Department of DermatologyKapens Norrins ScholarIndiana University School of MedicineIndianapolis, Indiana Raj Chovatiya, MD, PhD, MSCI, FAADAssistant Professor of DermatologyNorthwestern University Feinberg School of MedicineChicago, IllinoisThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/expert-insights-on-vitiligo-how-do-emerging-treatment-options-have-the-potential-to-transform-patient-outcomes 

Patients with metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) are widely treated with osimertinib, the preferred first-line treatment option. However, disease progression inevitably occurs, driven by EGFR-dependent or EGFR-independent mechanisms of resistance. Platinum-based chemotherapy is the recommended treatment following progression with osimertinib but responses to platinum-based chemotherapy are transient. Salvage therapies, which are used after progression on platinum-based chemotherapy, have poor clinical outcomes in addition to substantial toxicity. In this podcast, authors discuss the current treatment landscape and emerging therapeutic options for patients with metastatic EGFR-mutated NSCLC whose disease has progressed following treatment with osimertinib and platinum-based chemotherapy.   This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the XX website and by using this link: https://link.springer.com/article/10.1007/s12325-023-02680-1. All conflicts of interest can be found online.   Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

In this podcast, expert clinicians will discuss the current and emerging therapies for motor symptoms in Parkinson's disease.

CME credits: 1.00 Valid until: 26-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/new-hope-novel-and-emerging-treatment-options-rett-syndrome/15547/ Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.

Host: Mario R. Nacinovich, Jr., MSc Guest: Walter Koroshetz, MD Amyotrophic lateral sclerosis (ALS) is a rare neurogenerative disease, and organizations including the FDA and NIH are working to accelerate potential therapies. What's on the horizon for the treatment landscape? Mario Nacinovich joins Dr. Walter Koroshetz, who is the Director of the National Institute of Neurological Disorders and Stroke, to explore these new developments.

CME credits: 0.25 Valid until: 31-10-2023 Claim your CME credit at https://reachmd.com/programs/cme/retina-clinic-emerging-treatment-options-in-diabetic-retinopathy/13985/ Can we apply the new, more durable treatments in diabetic macular edema and neovascular age-related macular degeneration to the treatment of our patients with diabetic retinopathy? Join Dr. Peter Campochiaro and Dr. Roger Goldberg as they discuss ways these new approaches could benefit even more patients.

In this podcast, expert clinicians will discuss the emerging treatment options for CSU management.

Join 3 specialists in discussion about targets for treatment and putative mechanisms of action of emerging drugs for CKD-associated pruritus. Credit available for this activity expires: 5/2/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/970767?src=mkm_podcast_addon_970767

CME credits: 0.25 Valid until: 08-04-2023 Claim your CME credit at https://reachmd.com/programs/cme/a-new-light-in-higher-risk-mds-emerging-treatment-options/13517/ New and novel therapeutics for the treatment myelodysplastic syndrome (MDS) are in development. What are these agents, and how do they work? Listen in as Dr. Andrew Brunner and Dr. Amy DeZern discuss ongoing clinical trials, current data from those trials, and the future potential for tailoring treatment plans. Since the completion of this activity, the U.S. Food and Drug Administration has lifted the partial clinical hold placed on studies evaluating the investigational agent magrolimab in combination with azacytidine for the treatment of MDS and AML. https://clinicaltrials.gov/ct2/results?cond=&term=Magrolimab+&cntry=&state=&city=&dist=

CME credits: 0.25 Valid until: 08-04-2023 Claim your CME credit at https://reachmd.com/programs/cme/a-new-light-in-higher-risk-mds-emerging-treatment-options/13517/ New and novel therapeutics for the treatment myelodysplastic syndrome (MDS) are in development. What are these agents, and how do they work? Listen in as Dr. Andrew Brunner and Dr. Amy DeZern discuss ongoing clinical trials, current data from those trials, and the future potential for tailoring treatment plans. Since the completion of this activity, the U.S. Food and Drug Administration has lifted the partial clinical hold placed on studies evaluating the investigational agent magrolimab in combination with azacytidine for the treatment of MDS and AML. https://clinicaltrials.gov/ct2/results?cond=&term=Magrolimab+&cntry=&state=&city=&dist=

To obtain credit – Click Here For more information – Click Here

Emerging Treatment Options for COVID 19 I Dr Hemanth Thacker In Conversation with Dr Anil Pareek by TheRightDoctors

To encourage consistent, high quality, evidence-based treatment of patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), the AUA and Urology Care Foundation has produced a series of online activities and educational resources for healthcare professionals, patients and caregivers. One of those such activities is this complimentary Emerging Treatment Options for Non-Metastatic CRPC Podcast (2018). https://auau.auanet.org/node/20087

Host: John J. Russell, MD Guest: Thomas Doyle, MD About 40,000 babies are born with Congenital Heart Disease each year, making it one of the most common birth defects and causes of infant death in the US. CHD is usually present at birth but shows very few outward signs and, in most cases has no known cause or origin. New and evolving surgical techniques, along with the dawn of pediatric heart transplant, are transforming the field of pediatric cardiology and offer new options for CHD patients. Host Dr. John Russell talks with Dr. Thomas Doyle about how continued research, improved surgical treatments and, emerging technology have altered the course of treatment for CHD, resulting in approximately 69% of children with CHD now living to age 18. Dr. Thomas Doyle is the Ann and Monroe Carell Jr. Family Associate Professor of Pediatrics at Vanderbilt University. Dr. Doyle was a 2016 Project Heart CHD research grant recipient.

Host: John J. Russell, MD Guest: Thomas Doyle, MD About 40,000 babies are born with Congenital Heart Disease each year, making it one of the most common birth defects and causes of infant death in the US. CHD is usually present at birth but shows very few outward signs and, in most cases has no known cause or origin. New and evolving surgical techniques, along with the dawn of pediatric heart transplant, are transforming the field of pediatric cardiology and offer new options for CHD patients. Host Dr. John Russell talks with Dr. Thomas Doyle about how continued research, improved surgical treatments and, emerging technology have altered the course of treatment for CHD, resulting in approximately 69% of children with CHD now living to age 18. Dr. Thomas Doyle is the Ann and Monroe Carell Jr. Family Associate Professor of Pediatrics at Vanderbilt University. Dr. Doyle was a 2016 Project Heart CHD research grant recipient.

Host: John J. Russell, MD Guest: Thomas Doyle, MD About 40,000 babies are born with Congenital Heart Disease each year, making it one of the most common birth defects and causes of infant death in the US. CHD is usually present at birth but shows very few outward signs and, in most cases has no known cause or origin. New and evolving surgical techniques, along with the dawn of pediatric heart transplant, are transforming the field of pediatric cardiology and offer new options for CHD patients. Host Dr. John Russell talks with Dr. Thomas Doyle about how continued research, improved surgical treatments and, emerging technology have altered the course of treatment for CHD, resulting in approximately 69% of children with CHD now living to age 18. Dr. Thomas Doyle is the Ann and Monroe Carell Jr. Family Associate Professor of Pediatrics at Vanderbilt University. Dr. Doyle was a 2016 Project Heart CHD research grant recipient.

Host: John J. Russell, MD Guest: Thomas Doyle, MD About 40,000 babies are born with Congenital Heart Disease each year, making it one of the most common birth defects and causes of infant death in the US. CHD is usually present at birth but shows very few outward signs and, in most cases has no known cause or origin. New and evolving surgical techniques, along with the dawn of pediatric heart transplant, are transforming the field of pediatric cardiology and offer new options for CHD patients. Host Dr. John Russell talks with Dr. Thomas Doyle about how continued research, improved surgical treatments and, emerging technology have altered the course of treatment for CHD, resulting in approximately 69% of children with CHD now living to age 18. Dr. Thomas Doyle is the Ann and Monroe Carell Jr. Family Associate Professor of Pediatrics at Vanderbilt University. Dr. Doyle was a 2016 Project Heart CHD research grant recipient.

Jeffrey Zonder, MD is a professor of oncology at the Karmonos Cancer Institute in Detroit, Michigan. He has won teaching awards at Wayne State University in 2005 and 2007, is a member of the SWOG Barlogie-Salmon Myeloma Committee, serves as a medical advisor for Amyloidosis Support Groups, Inc, and runs the blog, Amyloid Planet. He spoke with Oncology Data Advisor at the 2016 Asheville Hematologic Malignancies Symposium about recently approved and emerging therapies in multiple myeloma, the greatest challenges still facing myeloma management, and how he uses social media to discuss new and exciting research. Discussion Notes: On establishing deeper responses with new and standard techniques [0:56] On the most exciting data from recent clinical trials and emerging therapies in multiple myeloma [1:52] On the greatest challenges still facing myeloma management [3:38] On using social media for an online journal club [4:42] On the future of myeloma therapies and the need for clinical trials [5:39]

Emerging Treatment Options for the Reversal of Oral Anticoagulant Therapy - Faculty Roundtable Discussion (Part 3 of 4) Part 3: Balancing Bleeding and Thrombosis Risk Faculty: Edith A. Nutescu, Pharm.D., FCCP, Chair and Moderator Clinical Professor The University of Illinois at Chicago College of Pharmacy Director, Antithrombosis Center The University of Illinois Hospital and Health Sciences System Chicago, Illinois William E. Dager, Pharm.D., BCPS (AQ-Cardiology) Pharmacist Specialist UC Davis Medical Center Sacramento, California James S. Kalus, Pharm.D., BCPS (AQ-Cardiology) Senior Manager, Patient Care Services Department of Pharmacy Services Henry Ford Hospital C.E. Credits: This activity is not eligible for continuing education credits.

Emerging Treatment Options for the Reversal of Oral Anticoagulant Therapy - Faculty Roundtable Discussion (Part 2 of 4) Part 2: Usefulness of Coagulation Assays in Patients taking Target-Specific Oral Anticoagulants Faculty: Edith A. Nutescu, Pharm.D., FCCP, Chair and Moderator Clinical Professor The University of Illinois at Chicago College of Pharmacy Director, Antithrombosis Center The University of Illinois Hospital and Health Sciences System Chicago, Illinois William E. Dager, Pharm.D., BCPS (AQ-Cardiology) Pharmacist Specialist UC Davis Medical Center Sacramento, California James S. Kalus, Pharm.D., BCPS (AQ-Cardiology) Senior Manager, Patient Care Services Department of Pharmacy Services Henry Ford Hospital C.E. Credits: This activity is not eligible for continuing education credits.

Emerging Treatment Options for the Reversal of Oral Anticoagulant Therapy - Faculty Roundtable Discussion (Part 1 of 3) Part 1: Issues Related to Warfarin Reversal Faculty: Edith A. Nutescu, Pharm.D., FCCP, Chair and Moderator Clinical Professor The University of Illinois at Chicago College of Pharmacy Director, Antithrombosis Center The University of Illinois Hospital and Health Sciences System Chicago, Illinois William E. Dager, Pharm.D., BCPS (AQ-Cardiology) Pharmacist Specialist UC Davis Medical Center Sacramento, California James S. Kalus, Pharm.D., BCPS (AQ-Cardiology) Senior Manager, Patient Care Services Department of Pharmacy Services Henry Ford Hospital C.E. Credits: This activity is not eligible for continuing education credits.